Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  Novo Nordisk A/S    NOVO B   DK0060534915

NOVO NORDISK A/S

(NOVO B)
  Report
Real-time Estimate Quote. Real-time Estimate CHI-X - 12/02 10:55:00 am
419.15 DKK   +0.52%
12/01NOVO NORDISK A/S : - Company announcements, trading in own shares
AQ
12/01NOVO NORDISK A/S : ESG presentation ()
PU
12/01NOVO NORDISK : Gets a Buy rating from JP Morgan
MD
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Novo Nordisk A/S : Alexander Mann Solutions partners with Novo Nordisk to support its global healthcare recruitment requirements

10/12/2020 | 04:57am EST

Novo Nordisk, a leading global healthcare company, founded in 1923 and headquartered in Denmark, has engaged Alexander Mann Solutions to support its retained recruitment activity across Europe, Middle East and Africa, Asia Pacific and Latin America.

Under this partnership, the global talent acquisition and management firm will provide Novo Nordisk with dedicated candidate sourcing teams around the world to identify and engage the best talent in the healthcare market, helping the company to achieve its mission of driving change to defeat diabetes and other serious chronic conditions. In addition, Alexander Mann Solutions will provide dedicated talent acquisition administration services to support both candidates and hiring managers throughout the entire recruitment process.

Jim Sykes, Sector Managing Director for Pharmaceutical and Life Sciences at Alexander Mann Solutions commented on the news:

"We are absolutely delighted to be partnering with Novo Nordisk and supporting its bold purpose to drive change to defeat diabetes and other serious chronic diseases. As talent acquisition experts with an unrivalled global footprint and deep expertise in the pharmaceutical market we know that we can deliver long-term strategic value to the business and best enable it to secure the talent it needs to deliver the company mission for many years to come. Since we began engaging with the organisation, we have felt a deep affinity with the business and recognised an alignment of our corporate values. Novo Nordisk is an inspirational company within its sector and we couldn't be more proud of this new partnership."

Alain Proietti, Vice President of Global Talent Acquisition added:

"In Novo Nordisk, we are pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Talented people are critical to our success. And with employees in 80 countries around the world, our ability to identify, engage with and hire the best talent in each of our geographies is paramount.

"The team at Alexander Mann Solutions has clearly demonstrated to us their ability to help us transform our Talent Acquisition function. Alexander Mann Solutions will not only bring us innovative technology, access to its network of global client service centres to support our hiring in EMEA, Asia Pacific and Latin America, but also a dedicated team of talent acquisition professionals who we know will represent our company with passion and pride. We are excited to embark on this new partnership with Alexander Mann Solutions and we look forward to seeing the results that it will bring."

ENDS

Press contact:

Vickie Collinge

BlueSky PR

vickie@bluesky-pr.com

+441582 790705

About Alexander Mann Solutions

We're passionate about helping companies and individuals fulfil their potential through talent acquisition and management. Today, over 4,500 of our talent acquisition and management experts partner with more than 100 blue-chip organisations, operating in 40 languages, and over 90 countries. We deliver a distinctive blend of outsourcing solutions and - through Talent Collective - a full range of consulting and specialist services. We provide unrivalled experience, capability and thought leadership to help clients attract, engage and retain the talent they need for business success. This approach has led to us being identified as a global leader in both the 2020 NelsonHall NEAT Matrix and the Everest Group PEAK Matrix® Assessment 2020. We also made the Sunday Times PwC Top Track 250 list for the third consecutive year.

www.alexandermannsolutions.com

.

(C) 2020 M2 COMMUNICATIONS, source M2 PressWIRE

All news about NOVO NORDISK A/S
12/01NOVO NORDISK A/S : - Company announcements, trading in own shares
AQ
12/01NOVO NORDISK A/S : ESG presentation ()
PU
12/01NOVO NORDISK : Gets a Buy rating from JP Morgan
MD
11/30Weight-Loss Firm Noom Names First CFO
DJ
11/23NOVO NORDISK A/S : – Share repurchase programme
AQ
11/20India's Gland Pharma jumps 23% in market debut
RE
11/18NOVO NORDISK A/S : - Once-weekly semaglutide 2.0 mg demonstrates superior reduct..
AQ
11/18NOVO NORDISK A/S : Experts Urge Govt to Subsidise Cost of Diabetes Management, T..
AQ
11/17NOVO NORDISK A/S : Once-weekly semaglutide 2.0 mg demonstrates superior reductio..
AQ
11/16GILEAD SCIENCES : and Novo Nordisk Present New Data from Proof-of-Concept Trial ..
AQ
More news
Financials
Sales 2020 127 B 20 692 M 20 692 M
Net income 2020 42 174 M 6 849 M 6 849 M
Net cash 2020 8 472 M 1 376 M 1 376 M
P/E ratio 2020 23,0x
Yield 2020 2,16%
Capitalization 974 B 158 B 158 B
EV / Sales 2020 7,57x
EV / Sales 2021 7,11x
Nbr of Employees 44 326
Free-Float 75,1%
Chart NOVO NORDISK A/S
Duration : Period :
Novo Nordisk A/S Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVO NORDISK A/S
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 27
Average target price 439,69 DKK
Last Close Price 417,00 DKK
Spread / Highest target 30,7%
Spread / Average Target 5,44%
Spread / Lowest Target -30,5%
EPS Revisions
Managers
NameTitle
Lars Fruergaard Jørgensen President & Chief Executive Officer
Helge Lund Chairman
Maziar Mike Doustdar Executive Vice President-International Operations
Karsten Munk Knudsen Chief Financial Officer & Executive Vice President
Mads Krogsgaard Thomsen Chief Science Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
NOVO NORDISK A/S7.85%156 152
JOHNSON & JOHNSON1.08%388 168
ROCHE HOLDING AG-4.59%284 650
PFIZER, INC.6.17%219 056
MERCK & CO., INC.-10.34%206 324
NOVARTIS AG-11.46%205 415